Alembic Pharmaceuticals Limited announced unaudited consolidated and standalone financial results for the first quarter ended June 30, 2018. For the quarter, on consolidated basis, the company's revenue from operations was INR 8,625.3 million against INR 6,481.9 million for the same period last year. Total income was INR 8,626.3 million against INR 6,483.6 million for the same period last year. Profit before tax was INR 1,219.2 million against INR 788.6 million for the same period last year. Profit for the period before share of profit of associates and joint ventures was INR 903.8 million compared to INR 633.8 million a year ago. Total comprehensive income for the period attributable to owners of the company was INR 978.0 million compared to INR 653.6 million a year ago. Basic and diluted earnings per share were INR 4.80 compared to INR 3.54 a year ago. EBITDA Pre R&D was INR 2,670 million compared to INR 1,950 million a year ago. EBITDA Post R&D was INR 1,510 million compared to INR 1,050 million a year ago. CapEx in the quarter is INR 1,560 million.

For the quarter, on standalone basis, the company's revenue from operations was INR 8,114.2 million against INR 5,901.1 million for the same period last year. Total income was INR 8,115.8 million against INR 5,903.4 million for the same period last year. Profit before tax was INR 1,453.0 million against INR 644.2 million for the same period last year. Net profit after tax for the period was INR 1,139.8 million compared to INR 506.7 million a year ago. Basic and diluted earnings per share were INR 6.05 compared to INR 2.69 a year ago.

For the fiscal year 2019, the company expects tax rate at 21%, 21.5%.